PRGO
36
3
WMT
70
2
KR
52
2
NWSA
71
-4
GOOG
81
-2
TJX
59
5
DG
14
2
HCP
54
-2
OI
30
5
JCI
44
2
NTRS
47
3
MSI
55
-2
CA
32
3
ED
42
2
NUE
43
2
GILD
58
2
KSS
42
3
VIX
15
7
CMA
48
2
EQT
45
-3
PRGO
36
3
WMT
70
2
KR
52
2
NWSA
71
-4
GOOG
81
-2
TJX
59
5
DG
14
2
HCP
54
-2
OI
30
5
JCI
44
2
NTRS
47
3
MSI
55
-2
CA
32
3
ED
42
2
NUE
43
2
GILD
58
2
KSS
42
3
VIX
15
7
CMA
48
2
EQT
45
-3
Financhill
Back

Xeris Biopharma Holdings 10K Form

Buy
58

XERS
Xeris Biopharma Holdings

Last Price:
$3.44
Seasonality Move:
-20.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2020-08-10 10Q XERS/Xeris Biopharma Holdings Quarterly
2020-05-07 10Q XERS/Xeris Biopharma Holdings Quarterly
2020-03-12 10K XERS/Xeris Biopharma Holdings Annual
2019-11-07 10Q XERS/Xeris Biopharma Holdings Quarterly
2019-08-06 10Q XERS/Xeris Biopharma Holdings Quarterly
2019-05-09 10Q XERS/Xeris Biopharma Holdings Quarterly

Receive XERS News And Ratings

See the #1 stock for the next 7 days that we like better than XERS

XERS Financial Statistics

Sales & Book Value

Annual Sales: $163.9M
Cash Flow: $-8.4M
Price / Cash Flow: 0
Annual Sales: $-0.19
Price / Book: 0

Profitability

EPS (TTM): -0.44000
Net Income (TTM): $-63.1M
Gross Margin: $135.3M
Return on Equity: -1019.2%
Return on Assets: -19.24%

Xeris Biopharma Holdings Earnings Forecast

Key Xeris Biopharma Holdings Financial Ratios

  • The Gross Profit Margin over the past 8 years for XERS is 82.52%.
  • The Selling, General & Administrative Expenses for XERS have been equal to 89.13% of Gross Profit Margin.
  • The Research & Development expenses have been 13.63% of Revenue.
  • The Interest Expense is -42.74% of Operating Income.
  • The Net Earning history of XERS is -37.98% of Total Revenues.
  • Per Share Earnings over the last 8 years have been positive in 6 years.

Xeris Biopharma Holdings Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: XERS
CUSIP: 98422L
Website: xerispharma.com

Debt

Debt-to-Equity Ratio: -8.17
Current Ratio: 1.79
Quick Ratio: 1.21

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

XERS Technical Analysis vs Fundamental Analysis

Buy
58
Xeris Biopharma Holdings (XERS) is a Buy

Is Xeris Biopharma Holdings a Buy or a Sell?